NJ-TOPCON-HEALTHCARE
25.6.2020 07:02:12 CEST | Business Wire | Press release
Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it has launched its new MYAH instrument to the European region. MYAH is a comprehensive management tool for eyecare professionals interested in building, managing and growing myopia and dry eye services within their practice or research institution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005855/en/
The versatile, all-in-one MYAH provides all the critical tools needed to support myopia management while also offering an evolving platform to add or grow dry eye management. MYAH incorporates corneal topography including keratoconus screening and pupillometry, axial length measurements by optical low coherence interferometry, progression reports for analyzing treatment efficacy, and a comprehensive suite of dry eye assessment tools. The instrument is compact, easy to operate, and offers rapid capture to ensure patient satisfaction.
With the launch of MYAH, Topcon achieves a milestone in the battle against the global myopia epidemic. It is estimated that 50% of the world’s population, including European regions, may be myopic by 20501 .
“MYAH is ideally suited to combat the growing crises of both myopia and dry eye disease. Its versatility and ease of use allows eyecare professionals to easily build a myopia service within their practice, educate patients on the implications of myopia and dry eye disease, manage their patients’ conditions, and grow their service offerings,” stated John Trefethen, Global VP of Marketing & Product Design for Topcon Healthcare.
For more information on MYAH, please visit www.topconmyah.com.
About Topcon Healthcare
Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multimodal imaging, vendor-neutral data management and ground-breaking remote diagnostic technology.
A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.
- Holden, BA, Fricke, TR, Wilson, DA et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016; 123:1036–42. Available from: doi: DOI: 10.1016/j.ophtha.2016.01.006
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005855/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera2.3.2026 08:00:00 CET | Press release
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE StudiesPrescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In addi
Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants2.3.2026 08:00:00 CET | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the expansion of its 5G RedCap portfolio with the launch of the RM255C-GL for global markets and the RG255C-NA for the North America market, further strengthening its mid-tier 5G offering for worldwide deployments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260301754857/en/ Quectel expands mid-tier 5G portfolio with new RedCap 3GPP release 17 variants As 5G expands further into industrial and IoT domains, the need for solutions that combine strong performance with cost efficiency is becoming increasingly critical. Positioned between high-speed eMBB and narrowband NB-IoT, 5G RedCap (Reduced Capability) has emerged as the ideal technology to address this mid-tier connectivity gap. With a comprehensive product portfolio and global deployment expertise, Quectel enables a seamless transition for mid-speed IoT applications moving toward sca
Thales sets a world first in quantum-safe security for 5G networks2.3.2026 08:00:00 CET | Press release
Thales has successfully demonstrated a world-first innovation that prepares 5G networks for the age of quantum computing, marking a major milestone for the global telecommunications industry. The collaboration with a top tier mobile operator, showed that existing 5G SIM / eSIM cards already deployed in the field can be securely upgraded to quantum-safe protection, without disrupting service or impacting the customer experience. This Post-Quantum Cryptographic (PQC) breakthrough proves that mobile networks can evolve their security through crypto agility to address quantum cyber threats. Quantum computing has the potential to break today’s encryption methods in the future, putting mobile communications, personal data and critical infrastructure at risk. For telecom operators, this is not a distant theoretical issue: 5G networks underpin everything from smartphones and connected vehicles to emergency services, industry and national infrastructure. This press release features multimedia.
NHOA Energy Announces Two Major MACSE Battery Projects2.3.2026 08:00:00 CET | Press release
The projects reinforce NHOA Energy’s leadership in the Italian market NHOA Energy, global provider of utility-scale energy storage systems, has been awarded two new Battery Energy Storage System (BESS) projects in Italy by a leading independent platform in the renewables and energy transition sector, with a total MACSE-contracted capacity of about 600 MWh and a total power of 90 MW. The two projects, located in Campania and Sardinia, represent NHOA Energy’s first systems awarded under MACSE (Meccanismo di Approvvigionamento di Capacità di Stoccaggio Elettrico), Italy’s new capacity mechanism dedicated to long-duration storage, and a milestone in the company’s growth in the national energy storage market. The projects, financed by a pool of top-tier Italian and international financial institutions, reaffirm NHOA Energy’s centrality as technology supplier and turnkey contractor in the Italian BESS market, built on extensive local and international experience, breadth of resources, intima
SES: Full Year 2025 Results2.3.2026 07:30:00 CET | Press release
SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the year ended 31 December 2025 FY25 Performance (€ million) 2025 as reported (1) 2024 as reported (1) ∆ at constant FX (2) 2025 like-for-like (3) 2024 like-for-like (3) ∆ at constant FX (2) Average €/$ FX rate 1.12 1.09 1.12 1.09 Revenue (4) 2,627 2,001 +33.9% 3,512 3,656 -1.6% Adjusted EBITDA (4) (5) 1,196 1,028 +19.1% 1,529 1,783 -12.1% 1) ‘Reported basis’ with Intelsat fully consolidated from 17 July 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX to neutralise currency variations 3) ‘Like-for-like basis’ as if Intelsat fully consolidated from 1 January 2024 4) Full-year 2025 results include the effects of purchase price accounting (PPA) related to Intelsat acquisition: Negative impact of €6m on revenue & €8m on Adj. EBITDA 5) Excluding operating expenses/income recognised in relation to U.S. C-band repurposing, other income non-recurring, fair value m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
